1995

(BW) BIO-FLUORESCENT-TECH)(BFTI) BFTI receives Peruvian naval approval to conduct trials for its rapid immunochromatographic assay for detection of the HIV 1/2 viruses
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - BW1028 DEC 28,1995 6:00 PACIFIC 09:00 EASTERN
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Dec. 28, 1995-- Bio-Fluorescent Technologies Inc. (OTC BB:BFTI) Thursday announced it had received approval from the Peruvian Ministry of Interior, which is in charge of the armed forces and police, to conduct trials with the navy. Tests will be conducted on 100 individuals using BFT


(BW) NeXstar Pharmaceuticals and Boehringer Mannheim to collaborate on antiviral drug development; Boehringer Mannheim makes equity investment in NeXstar
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 22 Dec 1995
BOULDER, Colo.--(BUSINESS WIRE)--Dec. 22, 1995--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that Boehringer Mannheim Therapeutics has licensed all rights to develop and market anti-HIV nucleoside-lipid conjugates based on NeXstar s patented lipid conjugate technology. Currently, Boehringer Mannheim has


(BW) (MEDICAL-DISCOVERIES)(MLSC) Medical Discoveries reports successful first phase evaluation of its patented sterilizing device
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 BW URL: http://www.hnt.com/bizwire - BW1095 DEC 20,1995 9:12 PACIFIC 12:12 EASTERN
SALT LAKE CITY--(BUSINESS WIRE)--Dec. 20, 1995--Medical Discoveries Inc. (NASDAQ Bulletin Board: MLSC) reported today that a preliminary study undertaken at Baylor College of Dentistry, Dallas, has successfully demonstrated the efficacy of the company s product, MDI-P, as a potential sterilizing agent for dental and me


(BW) (BIO-FLUORESCENT-TECH)(BFTI) BFTI receives Argentinean Health Ministry approval for its rapid immunochromotographic assays for the detection of the HIV 1/2 and Hepatitis "B" viruses
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 http://www.hnt.com/bizwire - BW1023 DEC 20,1995 5:59 PACIFIC 08:59 EASTERN
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Dec. 20, 1995-- Bio-Fluorescent Technologies Inc. (OTC BB:BFTI) Wednesday announced the receipt of Health Ministry registration for its rapid assay tests for the HIV 1/2 and Hepatitis B virus in Argentina . Product registration for import was granted Dec. 15, 1995. The company expect


(BW) Gen-Probe rapid tuberculosis test wins FDA approval; test uses genetic probe technology to dramatically cut detection time
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 18 Dec 1995.
SAN DIEGO--(BUSINESS WIRE)--Dec. 18, 1995--Gen-Probe Inc. Monday announced that its amplified test for Mycobacterium tuberculosis (M. tuberculosis or TB) has been approved by the Food and Drug Administration for use in the rapid diagnosis of tuberculosis in the United States . Once thought to be on its w


(BW) UC San Francisco and University of Pittsburgh researchers infuse baboon bone marrow cells into AIDS patient
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 Dec 1995.
SAN FRANCISCO--(BUSINESS WIRE)--Dec. 15, 1995--A team of physician-researchers from UC San Francisco and the University of Pittsburgh have infused bone marrow cells from a baboon into an HIV-infected patient in an attempt to restore his immune function. The procedure was performed on patient Jeff Getty on Thursday, Dec


(BW) AT&T and the Magic Johnson Foundation announce innovative technology grants to local HIV/AIDS organizations; grants are part of quarter million dollar commitment to Magic Johnson Foundation partnership
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 Dec 1995.
SAN FRANCISCO--(BUSINESS WIRE)--Dec. 15, 1995--In a unique effort to bring technology to the battle against AIDS, AT&T and the Magic Johnson Foundation (MJF) announced grants of more than $170,000 to 11 Bay Area nonprofit organizations and $100,000 to Los Angeles/Orange County agencies serving people with HIV/AIDS.


(BW) Enzo Biochem files patent application for GenSert universal gene delivery system; new product allows radically different approach in battle to combat AIDS
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 Dec 1995
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Dec. 15, 1995--Enzo Biochem Inc. (ASE:ENZ) announced today that it has filed an application with the U.S. Patent and Trademark Office related to a new gene delivery system that is designed to provide universal and efficient delivery of any gene to any cell. This universal gene delive


(BW) Structured Biologicals Inc. announces baboon experiment for AIDS therapy sponsored by Structured Biologicals Inc.
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Dec 14, 1995.
TORONTO--(BUSINESS WIRE)--Dec. 14, 1995--Avi Ben-Abraham, M.D., Chairman and Chief Executive Officer of Structured Biologicals Inc. ( SBI ) (SBL - Alberta Stock Exchange), announced today that an SBI sponsored experiment consisting of a bone marrow transplant from a baboon to an AIDS patient will take place today at a


(BW) Lifetech Corporation Appoints Director Dr. Roger Perrault, President Of The Industrial Biotechnology Association Of Canada, Appointed Director Of Lifetech Corporation
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Dec 12, 1995.
TORONTO, Ontario--(BUSINESS WIRE)--Dec. 12, 1995--LIFETECH CORPORATION(CANADIAN DEALING NETWORK: LFTK) LifeTECH Corporation, a development stage biotechnology company developing proprietary technology for blood sterilization, announced today that Dr. Roger Perrault, President of the Industrial Biotechnology Association


(BW) NeXstar Pharmaceuticals; DaunoXome shows promise as breast cancer treatment
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Dec 12, 1995.
BOULDER, Colo.--(BUSINESS WIRE)--Dec. 12, 1995--Data presented Tuesday at the 18th Annual San Antonio Breast Cancer Symposium shows that moderate-dose DaunoXome, NeXstar Pharmaceuticals liposomal formulation of the anticancer agent daunorubicin, is well-tolerated and has promising efficacy in treating advanced breast c


(BW) Chiron Vision Receives FDA Committee Recommendation To Approve Vitrasert Implant To Deliver CMV Retinitis Drug; Vitrasert Is First Drug Delivery Implant to Be Recommended For Local, Sustained Therapy of the Eye
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -Dec 8, 1995
SILVER SPRING, Md.--(BUSINESS WIRE)--Dec. 8, 1995--Chiron Vision, the ophthalmic business unit of Chiron Corporation (Nasdaq:CHIR), announced today that the Ophthalmic and Dermatologic Advisory Committee of the U.S. Food and Drug Administration ( FDA ) has recommended that the Vit


(BW) Ability of Immune System to Fight AIDS may be boosted by natural proteins: findings suggest new treatments
BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Nov 21, 1995
SAN FRANCISCO--(BUSINESS WIRE)--Nov. 21, 1995--A small group of people who are infected with the AIDS virus but who nonetheless have remained healthy for more than 10 years have immune cells that respond in a distinctive way to slow the progress of infection, researchers at the University of California San Francisco re



This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 1995. AEGiS.